
	Where results make sense

Topic: Eisai

Related Topics

Rinzai

Zen Buddhism

Dogen Zenji

Tendai

Japanese Buddhism

Kukai

Kimiko Date

List of Japanese people

Uji

Masayoshi Ito

Kofun

Kamakura, Kanagawa

Japan

Buddhism

Muromachi period

In the News (Sat 2 Jun 12)

EXECUTIVE POWER

Iran

ANALYSIS

Pakistan

Family compact

	Eisai - Wikipedia, the free encyclopedia
		Myōan Eisai, founder of the Rinzai School of Zen, 12th century.
		Faced with the opposition of traditonal schools of Buddhism such as Tendai, Shingon and Pure Land, Eisai finally left Kyoto for the north-east to Kamakura in 1199, where the Shogun and his warrior caste of Samurai enthusiastically welcomed his martial-arts-oriented Zen teachings.
		Eisai died in 1215 at the age of 75.
	en.wikipedia.org /wiki/Eisai (294 words)

	BostonWorks - Eisai Research Institute Jobs and Employer Profile
		Eisai's corporate philosophy focuses on meeting the diverse needs of patients and their families and increasing the benefits that health care provides.We express this philosophy with the phrase "human health care", and continue to concentrate efforts on its realization worldwide.
		Eisai's global R and D efforts are focused in several therapeutic areas, including central nervous system, oncology, gastrointestinal, and inflammatory diseases.
		Eisai Research Institute (ERI) in Andover, MA is the center for Eisai's U.S. research and development.
	bostonworks.boston.com /research/profiles/eisai_research_institute.shtml (352 words)

	Article - Myoan Eisai (Senko Kokushi 1141-1215) - presented by ©NewsFinder.Org - All Rights Reserved
		Eisai developed his Zen teaching in Japan carefully, for he wanted to establish a stable and enduring movement before drawing the attention of the imperial court or the monks of Mount Hiei.
		Eisai's qualifications and abilities could not be disputed, and so he concentrated on the charge that he should not teach because of his social position.
		Eisai died in 1215 at the age of seventy-five, honoured by many monks and mourned by the imperial court.
	www.newsfinder.org /more.php?id=366_0_1_0_M (2897 words)

	Gut and Gurgle U (Site not responding. Last check: 2007-10-08)
		Eisai and Janssen reserve the right to use any such communications, including without limitation any ideas, inventions, concepts, know-how, processes or techniques disclosed therein for any purpose whatsoever, including by reproducing, disclosing and distributing such information or otherwise using such information in connection with the development, manufacture and marketing of products or services.
		Please be advised that each of Eisai and Janssen (and their respective affiliates) actively and aggressively enforces its intellectual property rights to the fullest extent of the law.
		Eisai and Janssen recognize that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country.
	www.gutandgurgleu.com /legal.html (1162 words)

	Eisai Inc. Announces Completion of Zonegran(R) (zonisamide) Acquisition - FTC Authorizes Early Termination of HSR ...
		In the agreement, Eisai acquired exclusive North American and European manufacturing, development and marketing rights to Zonegran(R), which was developed and marketed by Elan for the adjunctive treatment of partial seizures in adult epilepsy.
		Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care company that discovers, develops and markets products in more than 30 countries.
		Eisai focuses its efforts in four therapeutic areas: neurology, gastrointestinal disorders, oncology and acute care.
	www.epilepsy.com /newsfeed/pr_1083159008.html (417 words)

	Eisai And Janssen Pharmaceutica Release: Aciphex (Rabeprazole Sodium) Appro... (Site not responding. Last check: 2007-10-08)
		Aciphex(R) is a registered trademark of Eisai Co., Ltd., Tokyo, Japan, and is co-promoted by Eisai Inc. and Janssen Pharmaceutica Inc. in the United States.
		Eisai Co., Ltd. (including its subsidiaries) had sales of $2.9 billion in fiscal year 2000* with approximately 14 percent of sales spent for research and development.
		Eisai Inc., a subsidiary of Eisai Co., Ltd., is based in Teaneck, NJ.
	www.acor.org /drugs/pipeline/news/7920715.story (970 words)

	Eisai Inc. Starts Major Expansion to Increase Pharmaceutical Sales Organization by 60 Percent
		About Eisai Inc. Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care company that discovers, develops and markets products in more than 30 countries.
		Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of more than $1 billion in fiscal year 2001 (year ending March 31, 2002).
		Eisai Inc. employs more than 600 people at its headquarters in Teaneck, N.J., at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, N.C., and in the field.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-05-2003/0001902571&EDATE= (463 words)

	Breaking Through (Site not responding. Last check: 2007-10-08)
		Eisai's drugs are in clinical trials to treat cancer and sepsis, a condition when a pathogen enters the blood which can be fatal over a short period of time.
		Eisai Research Institute employs 185 people, just a small fraction of the 1,500 people the company employs in the United States.
		Lewis, an original member of the four-person team that founded Eisai Research Institute, said he remembered a similar ceremony under a tent in the parking lot at 4 Corporate Drive back in the 1980s that took place in a driving rainstorm not unlike the thunderstorms of last Saturday.
	www.eagletribune.com /news/stories/20040824/BU_001.htm (982 words)

	MBC: Careers/Internships - Job Details
		Eisai?s corporate philosophy focuses on meeting the diverse needs of patients and their families and increasing the benefits that health care provides.
		Eisai?s global R & D efforts are focused in several therapeutic areas, including central nervous system, oncology, gastrointestinal, and inflammatory diseases.
		Eisai Research Institute (ERI) in Andover, MA, is the center for Eisai?s U.S. research and development, with an emphasis on finding new treatments for immune disorders and cancer.
	www.massbio.org /careers/detail.php3?JOB_ID=7984 (287 words)

	Eisai Co., Ltd. - Company Profile - Computer Business Review
		Eisai specializes in the manufacturing and marketing of pharmaceutical drugs, over-the-counter drugs and chemical and food additives.
		Eisai's second largest product segment, consumer healthcare products, encompasses non-prescription pharmaceuticals, such as the vitamin B2 preparation Chocola BB, the indigestion and heartburn remedy Saclon and the Juvelux series of natural vitamin E preparations, medicated topical treatments, cosmetics, toiletries and personal hygiene products.
		Eisai's corporate vision is to increase the benefits that health care provides, while always considering the desires of patients and their families.
	www.cbronline.com /companyprofile.asp?guid=B9A6F5D9-8EAC-4BCA-AB03-6798009A35B0 (1423 words)

	PRESS RELEASE Eisai Inc. Announces Launch of New CNS Sales Force (Site not responding. Last check: 2007-10-08)
		Eisai Inc. is a US pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care company that discovers, develops, and markets products in more than 30 countries.
		Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of more than $1.7 billion in fiscal year 2003 (year ending March 31, 2004).
		Eisai Inc. employs approximately 1,100 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in its CNS, neurology, primary care and hospital field forces.
	www.marketwire.com /mw/release_html_b1?release_id=70755 (434 words)

	Legal Notices - Eisai Medical Services Training Website - Eisai Inc.
		Eisai reserves the right to use any such communications, including without limitation, any ideas, concepts, know-how, processes or techniques for any purpose whatsoever, including by reproducing, disclosing and distributing such information or otherwise using such information in connection with the development, manufacture and marketing of products or services.
		Documents published by Eisai on eisaimedservtrain.com may not be copied, other than for non-commercial, individual reference with all copyright or other proprietary notices retained, and thereafter may not be recopied, reproduced or otherwise redistributed.
		Please be advised that Eisai actively and aggressively enforces its intellectual property rights to the fullest extent of the law.
	www.eisaimedservtrain.com /train/legal.asp (750 words)

	Japan Corporate News Network - Eisai's Statement to the AD2000 Clinical Trial Led by the Collaborative Group of the ... (Site not responding. Last check: 2007-10-08)
		Eisai and Pfizer Limited have reviewed the results of the study, and set the results of this new information in context with all other published evidence.
		Eisai and Pfizer are confident of the effectiveness of ARICEPT as the No.1 prescribed treatment of Alzheimer's disease supported by the rich evidence reported in 14 double-blind studies and long-term clinical studies.
		Eisai Co., Ltd. (TSE: 4523)(OTC: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries.
	www.japancorp.net /Article.Asp?Art_ID=7678 (521 words)

	PRESS RELEASE Eisai Inc. and U.S. Pharmacist Honor Pharmacists for Outstanding Service to Patients With Alzheimer's ... (Site not responding. Last check: 2007-10-08)
		Eisai discovered and developed Aricept® (donepezil hydrochloride tablets), the number-one prescribed medication worldwide for mild-to-moderate Alzheimer's disease.
		Eisai Inc. employs approximately 1,100 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field.
		Aricept® is co-promoted in the United States by Eisai Inc. and Pfizer Inc, which are dedicated to advances in Alzheimer's therapy.
	www.marketwire.com /mw/release_html_b1?release_id=74944 (1219 words)

	The Hindu Business Line : Eisai, GSK in pact for marketing anti-ulcer drug
		EISAI Pharmaceuticals India and GlaxoSmithKline Pharmaceuticals (GSK) have signed a co-promotion agreement to market the former's anti-ulcer drug, Paritec, in India.
		Eisai Co is the first Japanese pharmaceutical major to enter India and has a 100 per cent subsidiary in the country.
		Eisai's presence in India will be important for its global plans, he added.
	www.thehindubusinessline.com /2005/05/27/stories/2005052701720200.htm (476 words)

	About Eisai (Site not responding. Last check: 2007-10-08)
		Eisai Inc. upholds the belief in the dignity, integrity, and value of individual employees, and supports the premise that we are a company which will attract and retain the highest quality employees.
		Eisai's reputation for honesty, fairness, candor, and respect in all of its business dealings is directly attributable to the conduct of its employees.
		It is the policy of Eisai to provide equal opportunity in all areas of its employment practices without discrimination because of race, creed, color, sex, age, national origin, handicap, or veteran status.
	www.medzilla.com /abouteisai.html (236 words)

	500-Worker Florida Operation Navy Federal's First Outside HQ Area, Site Selection Online Insider
		Eisai USA Inc., the company's U.S. subsidiary, already owns the vacant 23-acre (nine-hectare) site for the RandD facility, which will be located some 24 miles (38 kilometers) north of downtown Boston.
		Eisai from 1998 and 2001 moved from No. 44 in U.S. pharmaceutical revenues to No. 23.
		Eisai took an initial step in that direction in January.
	www.conway.com /ssinsider/pwatch/pw030127.htm (2083 words)

	Recruiting drive in New Jersey for Japanese drug maker, Pharmaceutical News, Cover Story, Jobwerx.com
		Eisai was established as the full-fledged American subsidiary of its parent Japanese drug maker, Eisai Co. Ltd., in Teaneck in 1995.
		Now, Eisai is bursting at the seams at its Teaneck headquarters at the Glenpointe Centre office complex.
		There are about 10 or 12 in Bergen County and they have the same goals, to have a business presence in the United States, but they are a little bit earlier in their development and therefore have a little longer to go.
	www.jobwerx.com /news/Archives/recuriting_drive.html (1252 words)

	Healthcare Sales & Marketing Network News: Eisai Inc. Opens New Facility in Research Triangle Park To Accommodate ...
		Soichi Matsuno, Chairman and CEO of Eisai Inc., Bill Sheldon, President and COO of Eisai Inc., James Fain, North Carolina Secretary of Commerce, and Jim Roberson, President and CEO of the Research Triangle Foundation of North Carolina, the not-for-profit owner and developer of Research Triangle Park.
		Eisai Inc.'s Research Triangle Park facility manufactures Aricept® (donepezil hydrochloride tablets), the most widely prescribed treatment in the world for the symptoms of mild-to-moderate Alzheimer's disease, and Aciphex® (rabeprazole sodium), indicated for the treatment of symptomatic gastroesophageal reflux disease (GERD) including the healing and symptomatic relief of erosive GERD.
		Aricept® is a registered trademark of Eisai Co., Ltd., and is co- promoted in the United States by Eisai Inc. and Pfizer Inc, who are dedicated to advances in Alzheimer's therapy.
	salesandmarketingnetwork.com /news_release.php?ID=12702 (1391 words)

	Drug firm size will quadruple (Site not responding. Last check: 2007-10-08)
		Eisai Research Institute is a subsidiary of Tokyo-based Eisai Co. Ltd., the 20th-largest pharmaceutical company worldwide in total sales.
		Eisai also maintains research and sales facilities in Tsukuba, Japan; Research Triangle Park in North Carolina; and Teaneck and Ridgefield, N.J. "It's fabulous news for Andover," said Selectmen Chairman Brian Major, who works at nearby Philips Medical Systems.
		Eisai's expansion, which has been in the works for four years, adds to the growing cluster of medical-device makers and other medical firms in the River Road-Interstate 93 industrial area of West Andover.
	www.eagletribune.com /news/stories/20040819/FP_001.htm (579 words)

	Eisai Inc pharmaceutical company, research and product information
		Eisai Inc. (pronounced ā-zī) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2 billion in fiscal year 2004 (year ending March 31, 2005).
		Headquartered in Teaneck, New Jersey, we're dedicated to a tradition of genuine concern for people and are driven by the desire to meet the diverse health care needs of patients and their families and caregivers.
		We are an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co., Ltd., which has a strong and lasting commitment to the U.S. market.
	www.eisai.com (377 words)

	TorreyPines Therapeutics and Eisai Co., Ltd Enter Into a New Alliance Regarding a Novel Genetic Research Program for ...
		Eisai Co., Ltd. (President & CEO: Haruo Naito) and TorreyPines Therapeutics, Inc. (President & CEO: Neil Kurtz, M.D.) today jointly announced the signing of a new research agreement that focuses on the discovery of genes responsible for late onset Alzheimer's disease.
		Eisai is a global leader in Alzheimer's disease research and treatment.
		Eisai has been committed to discovering next generation treatments for Alzheimer's disease with multi-faced approaches targeted at production inhibition and antibody of beta-amyloid, which is believed to be responsible for the onset of Alzheimer's disease.
	www.freshnews.com /news/biotech-biomedical/article_27339.html (1247 words)

	Biospace.com (Site not responding. Last check: 2007-10-08)
		A second collaboration agreement between TorreyPines and Eisai was signed in February of this year to support the discovery of small molecules that lower A-beta42, a peptide involved in the creation of amyloid plaques, a hallmark of Alzheimer's disease.
		Eisai's decision is based on Phase II study results that showed a reduction in mortality in eritoran-treated patients versus placebo.
		Eisai plans to initiate a Phase III clinical program after consulting with regulatory authorities in the United States, Canada and European Union.
	www.biospace.com /news_company.cfm?CompanyID=2066&SR=51 (756 words)

	Phytomedics Inc. and Eisai Research Institute of Boston, Inc. Enter Cancer Therapeutic Discovery Collaboration :: ...
		``We are very pleased to be working with Eisai to discover and develop novel plant-derived therapeutic agents to combat cancer,'' said Dr. Bertold Fridlender, CEO of Phytomedics Inc. ``Eisai's advanced screening tools complement Phytomedics' unique and proprietary plant-based lead discovery and development technologies.
		Eisai Research Institute of Boston, Inc. conducts innovative research and development of pharmaceuticals for the treatment of inflammatory diseases and cancer through a unique Target Oriented, Chemistry Integrated approach.
		Eisai Research Institute is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care company that discovers, develops and markets products in more than 30 countries.
	www.npicenter.com /anm/anmviewer.asp?a=2434&z=3 (483 words)

	Current Science News - Eisai Submits Application to FDA for ARICEPT(R) for Treatment of Severe Alzheimer's Disease (Site not responding. Last check: 2007-10-08)
		ARICEPT, which is co-promoted in the United States by Eisai Inc. and Pfizer Inc, is currently approved for treatment of mild to moderate AD.
		Eisai Medical Research Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. Eisai Medical Research Inc. was established to focus solely on clinical research and to expedite clinical drug development of new chemical entities and of new indications for marketed products.
		Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2 billion in fiscal year 2004 (year ended March 31, 2005).
	www.lifesciencesworld.com /news/news-6096.htm (685 words)

	Globeinvestor.com: Iconix Initiates Chemogenomic Profiling Relationship with Eisai Co., Ltd.
		Working with Iconix, Eisai scientists hope to gain an early understanding of the potential toxicology, off-target effects and mechanisms of action of their compounds.
		Jim Neal, CEO of Iconix, said, "Eisai's decision to analyze their candidate molecules using chemogenomic tools reinforces both the increasingly important role of toxicogenomics and chemogenomics in forward-thinking drug discovery strategies, and the leading position of Iconix as the world's premier provider of this technology and capability."
		Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries.
	www.globeinvestor.com /servlet/WireFeedRedirect?cf=GlobeInvestor/config&vg=BigAdVariableGenerator&date=20030414&archive=prnews&slug=2003_04_14_08_2312_915061 (620 words)

Try your search on: Qwika (all wikis)